oxytetracycline--anhydrous and Bacteremia

Mycoplasma haemocanis is a hemotropic bacterium that can be associated with acute hemolytic disease in immunocompromised or splenectomized dogs. The present case report describes for the first time the use of real-time quantitative polymerase chain reaction (qPCR) to monitor M. haemocanis infection in a splenectomized dog. The report also describes the application of real-time qPCR for the analysis of deoxyribonucleic acid extracted from stained blood films. The analysis of blood films from the time of initial presentation allowed a retrospective confirmation of M. haemocanis infection. The M. haemocanis copy numbers remained high throughout antibiotic treatment of this dog. A decline in copy numbers was only recorded after 11 months of therapy, when improvements in clinical and hematological indices were also noted. Clearance of infection was not achieved, and the dog remained positive for M. haemocanis at 3.5 months postcessation of antibiotic therapy. Cytological examination of blood films for the presence of organisms was insensitive for the detection of parasitemia.

Topics: Animals; Anti-Bacterial Agents; Bacteremia; Dog Diseases; Dogs; Male; Mycoplasma; Mycoplasma Infections; Oxytetracycline; Polymerase Chain Reaction; Splenectomy

To develop a PCR assay for Candidatus Mycoplasma haemolamae (CMhl) infection in alpacas and use it to study the efficacy of oxytetracycline treatment and development of a subclinical carrier state.. 8 healthy adult alpacas.. Alpacas initially had negative results for CMhl in blood samples via PCR assay and were experimentally infected with CMhl; 4 were treated with oxytetracycline, and 4 were not treated. All were monitored regularly via PCR assay, blood smear examination, PCV, rectal temperature, and physical examination. At 6 months after treatment, all alpacas were immunosuppressed by administration of dexamethasone and tested for CMhl.. 7 of 8 alpacas had positive PCR assay results 4 to 6 days after experimental infection. When organisms were detectable on a blood smear, they were seen 2 to 6 days after positive results of PCR assay. Infection was often associated with mild anemia that was usually transient. No alpacas became hypoglycemic. Oxytetracycline treatment was not associated with faster clearance of organisms or resolution of anemia, and 4 of 4 treated alpacas still had positive results of PCR assay when immunosuppressed 6 months later; 0 of 3 nontreated alpacas had positive results of PCR assay following immunosuppression. Transient fever was detected in 3 alpacas during immunosuppression.. The PCR assay was more sensitive than blood smear examination for detection of infection. Clinical signs, anemia, and fever were not necessarily associated with infection. Oxytetracyline administration did not consistently clear CMhl infection. Although treated with oxytetracycline, infected alpacas remained chronic carriers.

Topics: Animals; Anti-Bacterial Agents; Bacteremia; Camelids, New World; Carrier State; DNA Primers; DNA, Bacterial; Mycoplasma; Mycoplasma Infections; Oxytetracycline; Polymerase Chain Reaction

Calves vaccinated with Anaplasma centrale were treated with 20 mg/kg of long-acting oxytetracycline (OTC/LA) before or simultaneously with vaccination or up to seven months later. Of 40 animals given one or two of OTC/LA from 3 to 13 days before vaccination, 23 become patent after vaccination, with an average prepatent period almost twice as long as that in non-treated vaccinated controls. Upon challenge with 2 x 10(8) A. centrale per dose all 17 previously non-patent calves showed average maximum parasitemias of 2 to 3.8%. Out of 30 calves treated with two to four doses of OTC/LA from one to four weeks after vaccination, 29 remained negative for A. centrale and reacted to challenge infection with average maximum parasitemias of 6.9-7.8%. Five out of 10 calves receiving OTC/LA simultaneously with the vaccination, and all of a separate group of 10 calves treated with a single dose seven days after vaccination, become patent an average of 51.6 and 63.5 d, respectively, after vaccination. Upon challenge, the five previously non-patent calves showed an average of 5.2% maximum parasitemia. In all groups, only rare parasites were seen in previously patent calves after challenge. Thirty calves treated with 2-4 doses of OTC/LA about six months after vaccination showed no or only a few parasites upon challenge. The above results show that treatment with single or multiple doses of OTC/LA a few weeks before or after administration of live A. centrale vaccine can interfere with elaboration of immunity.

Topics: Anaplasma; Anaplasmosis; Animals; Bacteremia; Bacterial Vaccines; Cattle; Cattle Diseases; Female; Immunity, Active; Oxytetracycline; Vaccination

Topics: Animals; Bacteremia; Mice; Neomycin; Oxytetracycline; Radiation; Radiation, Ionizing; Sepsis; Streptomycin

Topics: Anti-Bacterial Agents; Bacteremia; Humans; Oxytetracycline; Sepsis; Surgery, Oral; Tooth Extraction

Topics: Bacteremia; Bacteriology; Erythromycin; Humans; Meningitis; Oxytetracycline; Sepsis; Staphylococcal Infections

Topics: Bacteremia; Bacteriology; Humans; Oxytetracycline; Proteus; Proteus Infections; Sepsis; Streptomycin

Topics: Bacteremia; Humans; Oxytetracycline; Salmonella